NVS acquired AAAP in Oct 2017, thereby gaining ownership of Lutathera, a radioligand for neuroendocrine tumors. NVS paid a 47% premium in an all-cash deal valued at $3.9B.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.